Search En menu en ClientConnect
Search
Results
Top 5 search results See all results Advanced search
Top searches
Most visited pages

    Signature(s)

    Amount
    € 75,000,000
    Countries
    Sector(s)
    Germany : € 75,000,000
    Industry : € 18,750,000
    Services : € 56,250,000
    Signature date(s)
    27/06/2020 : € 18,750,000
    27/06/2020 : € 56,250,000
    Link to source
    Data sheet

    Summary sheet

    Release date
    3 April 2020
    Status
    Reference
    Signed | 27/06/2020
    20200248
    Project name
    Promoter - financial intermediary
    CUREVAC (IDFF)
    CUREVAC AG
    Proposed EIB finance (Approximate amount)
    Total cost (Approximate amount)
    EUR 75 million
    EUR 275 million
    Location
    Sector(s)
    Description
    Objectives

    The project supports a biotech company to develop a prophylactic vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The eligible investment plan includes Research, Development and Innovation (RDI)and related expenses to finance the development of the product and its subsequent commercial manufacture on a very large scale.

    The proposed transaction will support RDI and manufacturing investments required to bring a product to the market addressing a high unmet medical need, for the current COVID-19 crisis. By co-investing in the project, the EIB contributes to improving healthcare, whilst also fostering the generation of European scientific knowledge and acumen, preserving and cultivating highly skilled employment opportunities.

    Environmental aspects
    Procurement

    The project mainly concerns investments in RDI that are expected to be carried out in the promoter's existing facilities or other research centres already authorised for the same purpose and would therefore not require an Environmental Impact Assessment (EIA) under the Directive 2014/52/EU amending the EIA Directive 2011/92/EU. Investments are also expected to be made into the furnishing and validation of an existing manufacturing facility, this aspect of the project falls under the annex II of the EIA directive (2014/52/EU), referring to the manufacture of pharmaceutical products. Full environmental details will be verified during appraisal, including evidence of any screening by the competent authorities.

    The promoter is a private company, not operating in the utilities sector and does not have the status of a contracting authority; thus the project is not covered by the EU directives on procurement. However, the promoter's procurement procedures are expected to be in line with EIB guidelines for private sector projects. Details will be assessed during the project's due diligence.

    Link to source
    Summary sheet

    Disclaimer

    Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. The information and data provided on this page are therefore indicative.
    They are provided for transparency purposes only and cannot be considered to represent official EIB policy (see also the Explanatory notes).

    Documents

    Environmental and Social Data Sheet (ESDS) - CUREVAC (IDFF)
    Publication Date
    1 Jul 2020
    Document language
    Main Topic
    Lending
    Document Number
    129164193
    Document Focus
    Environmental Information
    Project Number
    20200248
    Sector(s)
    Regions
    Countries
    Publicly available
    Download now

    News & Stories

    Photogallery

    General enquiries and comments

    The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities.
    Enquiries and comments concerning the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.
    Alternatively, the EIB can be contacted through its external offices.
    Queries regarding details of a specific project, in particular when it is under appraisal by the EIB, should preferably be addressed directly to project promoters.

    Media enquiries

    Media-related enquiries can be addressed to the EIB Press Office. Please also visit our Media information section.

    Complaints mechanism

    Any complaint regarding alleged maladministration can be lodged via the EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

    Zero tolerance against fraud and corruption

    The EIB has a zero tolerance policy on fraud or corruption. To report allegations of fraud and corruption relating to EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential and handled in line with the EIB investigation procedures and the Anti-Fraud Policy.

    Related publications